<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A443B082-8B4B-463D-A312-5F3708DE6FC0"><gtr:id>A443B082-8B4B-463D-A312-5F3708DE6FC0</gtr:id><gtr:name>Novozymes</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A443B082-8B4B-463D-A312-5F3708DE6FC0"><gtr:id>A443B082-8B4B-463D-A312-5F3708DE6FC0</gtr:id><gtr:name>Novozymes</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/782A4DB8-9169-46F8-8C93-1EE564C0EE63"><gtr:id>782A4DB8-9169-46F8-8C93-1EE564C0EE63</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12024"><gtr:id>78CB82A5-A299-43DF-833B-BAB7509E4B35</gtr:id><gtr:title>Confidence in Concept 2012 - University College London</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12024</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-11-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Marsh CiC project collaboration with GlaxoSmithKline (GSK)</gtr:description><gtr:id>49EDADB5-4AA5-4AEF-A0A5-B710D7461543</gtr:id><gtr:impact>Further compounds have been avaialble for testing. Too early to know ultimalte benefit.</gtr:impact><gtr:outcomeId>546372cfce57b0.32640825-1</gtr:outcomeId><gtr:partnerContribution>Contribution of analogue compounds of active hits from screening.</gtr:partnerContribution><gtr:piContribution>Drug discovery for novel anti-vrial treatments</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research Technology (CRT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ashcroft CiC collaboration with CRT</gtr:description><gtr:id>3BFA4DAC-CB7F-4DDF-AACF-F7AC5F3456D3</gtr:id><gtr:impact>Active inhibitory compounds that form the basis of subsequent grant applications.
Multi-disciplinary: Cell biology, medicinal chemistry, synthestic organic chemistry</gtr:impact><gtr:outcomeId>5463717945b618.15986597-1</gtr:outcomeId><gtr:partnerContribution>CRT provided basic bioassay resource and some medicinal chemistry support.</gtr:partnerContribution><gtr:piContribution>Discovery of novel HIF pathway inhibitors for the treatment of cancer. UCL group provides project leadership, disease and HIF biology background knowledge and expertise along with medicinal chemistry and complex bioassay capabilities.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novozymes</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Caddick CiC project collaboration with Novozymes</gtr:description><gtr:id>3F818EF6-AEF4-4A7D-8A44-D9F0D537A81D</gtr:id><gtr:impact>Too early to report on specific outcomes.</gtr:impact><gtr:outcomeId>546364b711ec56.03320986-1</gtr:outcomeId><gtr:partnerContribution>The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology with ThioLogics' site-specific second generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.</gtr:partnerContribution><gtr:piContribution>Thiologics is a UCL Business PLC (UCLB) wholly owned company spun-out of UCL Chemistry. The company aims to commercialise new bioconjugation technologies developed in the laboratories of Professor Stephen Caddick and Dr James Baker. ThioLogics is particularly focused on delivering technology that will enable the construction of homogeneous antibody-drug conjugate therapeutics (ADCs).
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology with ThioLogics' site-specific second generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>29476</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PoC Fund - Caddick</gtr:description><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:id>848CC5A4-BBEB-42F0-9A8B-FBE42923E56C</gtr:id><gtr:outcomeId>58c67c502dc882.35127512</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>863521</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UTF - Niedle</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:id>04984493-8998-44A2-8964-55A9AD11087D</gtr:id><gtr:outcomeId>58c67e8f01c950.01109589</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Quinquennial Programme Grant - Mark Marsh</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C2551538-26B8-43E1-AB9C-B1DB23B7FA04</gtr:id><gtr:outcomeId>58c679fc8e6894.44212992</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>54996</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Business PoC Award - Towers</gtr:description><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:id>6628583F-0910-41EF-9C08-894A14F416A7</gtr:id><gtr:outcomeId>56e15a19aefec0.48122362</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>UCLH BRC SBC technology evaluation grant - Caddick</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>28E3CF2B-3229-4E55-B7C2-CC7DA71A21CF</gtr:id><gtr:outcomeId>58c67d0914c7b5.49657253</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460940</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - O'Brien</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F459F7F2-C823-4FF5-B560-96095900426D</gtr:id><gtr:outcomeId>58c68b5e368fe9.10719555</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Support Award (SBC) - Caddick</gtr:description><gtr:fundingOrg>Albumedix Ltd</gtr:fundingOrg><gtr:id>A1FAE220-1220-49BA-BB94-0B016D1E2A23</gtr:id><gtr:outcomeId>58c67e251db545.20621278</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99476</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Johnson and Johnson Innovation Fund - Neidle</gtr:description><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>560A047D-B29C-4E38-A4D8-6BDB0ABC9849</gtr:id><gtr:outcomeId>56e15350529601.15915073</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>132000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC PhD CASE studentship (in partnership with Syngenta) - Neil Millar</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>6ED3B8AF-0EBC-432F-A17C-72026B184B83</gtr:id><gtr:outcomeId>58c67aed246741.16941255</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Response mode grant - Caddick</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>B932DC7D-F177-4934-A5CF-1CDA91AD185C</gtr:id><gtr:outcomeId>58c67d5be12fb1.61653972</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59387</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Therapeutic Innovation Fund - Towers</gtr:description><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>A460E3C5-E4E5-4C97-80CC-7AB001712E20</gtr:id><gtr:outcomeId>56e15ab531f3f2.57720907</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600107</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Super follow-on Fund - Caddick</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>F3BF8B54-E0EA-457C-8108-593D46965909</gtr:id><gtr:outcomeId>58c67c03cae329.64296591</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199555</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>UCLH/UCL BRC grant - Towers - Development of broad specificity anti-viral drugs</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A3651D96-1CFA-45EC-B2EE-DB6AEC550DFF</gtr:id><gtr:outcomeId>58c6792f021d82.92183371</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK/Bayer Drug Discovery Award - Ashcroft</gtr:description><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>4CDD2EE8-3AC5-4080-ACD2-5ABA1E61F771</gtr:id><gtr:outcomeId>58c67b8d521fd0.20635176</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29476</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Business Proof of Concept - Caddick</gtr:description><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:id>9BB33684-E971-44D6-90DA-632FEE66E3F2</gtr:id><gtr:outcomeId>56e1579c2a2114.83831563</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2121162</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Senior Research Fellowship</gtr:department><gtr:description>Wellcome Trust Senior Biomedical Research Fellowship - Towers</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>6647A738-37D3-43BE-B8DE-3D351A54B56D</gtr:id><gtr:outcomeId>56e1598c6628d5.95487632</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides inhibitors of hypoxia-inducible factors (HIF), and their use in the prevention or inhibition of diseases characterized by abnormal HIF activity or levels, such as tumor progression, and the treatment of cancer. The invention encompasses pharmaceutical compns. with a mechanism of action for blocking elevated HIF activity in diseases, such as cancer.</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>3850E076-7E69-40F9-984D-AEDBA2769BEF</gtr:id><gtr:impact>To be determined</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e178d8147794.97810900</gtr:outcomeId><gtr:patentId>WO 2015079213</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Antitumor HIF inhibitors</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This is IP arising from the Caddick CiC award. Novel linkers for controlled conection of drug molecules to anibodies in the formation of Antibody-Drug-Conjugates (ADCs)</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>1CF98190-DC93-42C9-9687-A61834B8BF6D</gtr:id><gtr:impact>Early days, but has the potenrtial to transform the production of homogeneous ADCs</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>546375a5a5b987.42991480</gtr:outcomeId><gtr:patentId>WO/2013/132268</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Chemical modification of antibodies</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This invention discloses n on-immunosuppressive cyclosporin derivatives as antiviral agents</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>85EAA5CB-86F4-4168-AA82-481CEED1E1CF</gtr:id><gtr:impact>To be determined</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e17b169b0433.67795454</gtr:outcomeId><gtr:patentId>WO 2014132084</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to novel compounds which are naphthalene diimides. The compounds are used in therapy, particularly in cancer treatment.</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>2575012A-FF9F-417A-86B3-FEA5863B6249</gtr:id><gtr:impact>To be determined</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e174a8e706a3.14399500</gtr:outcomeId><gtr:patentId>PCT/GB2008/051131</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>NAPHTHALENE DIIMIDE COMPOUNDS INTERACTING WITH G-QUADRUPLEX REGIONS IN DNA</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>COMPOUNDS AND THEIR SYNTHESIS&amp;quot; (LIGHT ACTIVATED FLUORINATION) - hNET-Targeting Pro-Drugs for Treatment of Neuroblastoma</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>BD1C6A01-CEE6-4DE0-A2EC-26E1B1C9D680</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c681cb7fc714.77466425</gtr:outcomeId><gtr:patentId>PCT/GB2013/052678</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>COMPOUNDS AND THEIR SYNTHESIS&amp;quot; (LIGHT ACTIVATED FLUORINATION)</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to bis(triazolyl)naphthalene derivatives as G-quadruplex stabilizing agents, and their prepn., useful in the treatment of proliferative disease including cancer, in particular renal cancer.</gtr:description><gtr:grantRef>MC_PC_12024</gtr:grantRef><gtr:id>E1D24EB4-E700-404F-86CF-C449F948DA19</gtr:id><gtr:impact>To be determined</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e175e25e4aa0.68064137</gtr:outcomeId><gtr:patentId>WO 2012136997</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Preparation of bis(triazolyl)naphthalene derivatives as G-quadruplex stabilizing agents useful in treatment of proliferative disease</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Thiologics Limited</gtr:companyName><gtr:description>Thiologics is a UCL Business PLC (UCLB) wholly owned company spun-out of UCL Chemistry. The company aims to commercialise new bioconjugation technologies developed in the laboratories of Professor Stephen Caddick and Dr James Baker. ThioLogics is particularly focused on delivering technology that will enable the construction of homogeneous antibody-drug conjugate therapeutics (ADCs). For further information, please contact Dr Chris Williams, Business Development Manager, c.williams@thiologics.com.</gtr:description><gtr:id>18AD29DE-3D03-41D3-98A2-A4E66344B6FF</gtr:id><gtr:impact>Development of novel highly specific linker technologies used in the generation of Antibody-Drug-Conjugates</gtr:impact><gtr:outcomeId>546377b534d5f8.09788205</gtr:outcomeId><gtr:url>http://www.thiologics.com/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>34EE9901-669C-46C7-9E9B-03D6FA0965F1</gtr:id><gtr:title>Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41d07c6642da857b4cdb6114ef116a0"><gtr:id>f41d07c6642da857b4cdb6114ef116a0</gtr:id><gtr:otherNames>Bryden F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>56e13ce0258802.64838731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B5F228-7E7E-497A-A202-91D3E1FC5A86</gtr:id><gtr:title>Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/585b5a0d18d3edf2e7afcf5be81e492d"><gtr:id>585b5a0d18d3edf2e7afcf5be81e492d</gtr:id><gtr:otherNames>Schumacher FF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56e06359e08379.50312450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89D7409E-B101-4BE1-B023-56D5AAE0D447</gtr:id><gtr:title>HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d09dc58a9541cee561e377d010fb9896"><gtr:id>d09dc58a9541cee561e377d010fb9896</gtr:id><gtr:otherNames>Jacques DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58c677db40c443.92459459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE25CB80-1914-4813-B123-71D69363789A</gtr:id><gtr:title>A mild TCEP-based para-azidobenzyl cleavage strategy to transform reversible cysteine thiol labelling reagents into irreversible conjugates.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/709dfdb2e972430194790671d71e352b"><gtr:id>709dfdb2e972430194790671d71e352b</gtr:id><gtr:otherNames>Maruani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56e13b0eb3bbc1.73752411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B87311B-5BCC-453F-86CB-7A7FDA9CF0F5</gtr:id><gtr:title>Autophagy gene expression profiling identifies a defective microtubule-associated protein light chain 3A mutant in cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad132f288ab3a9e158b8d87fb3db484c"><gtr:id>ad132f288ab3a9e158b8d87fb3db484c</gtr:id><gtr:otherNames>Costa JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c677daa7fb43.76588814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC00088-C682-4066-9995-4A6CCF714CA9</gtr:id><gtr:title>Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/709dfdb2e972430194790671d71e352b"><gtr:id>709dfdb2e972430194790671d71e352b</gtr:id><gtr:otherNames>Maruani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56e05fe971b4a4.52465325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEF5BD6A-3455-4AD1-AE51-662A0F18C195</gtr:id><gtr:title>A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b77bc6a4e32db0241e6065e5b24f68bc"><gtr:id>b77bc6a4e32db0241e6065e5b24f68bc</gtr:id><gtr:otherNames>Smith ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56e0625b6c5092.67369274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EFC46C1-7166-48E3-BC69-CCCB8D02BC52</gtr:id><gtr:title>HIV-1 evades innate immune recognition through specific cofactor recruitment.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34c1e8ababaaac31f24b1fb218be5bbb"><gtr:id>34c1e8ababaaac31f24b1fb218be5bbb</gtr:id><gtr:otherNames>Rasaiyaah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>54635d923909a0.30310036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F5087BC-07D1-4CB0-9144-C577B5C35A5A</gtr:id><gtr:title>A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/709dfdb2e972430194790671d71e352b"><gtr:id>709dfdb2e972430194790671d71e352b</gtr:id><gtr:otherNames>Maruani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56e0625bd5e602.19007587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51F11729-A43B-4AC0-8AEA-1C8B8DAA2945</gtr:id><gtr:title>Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6542cfc5594084c9f07eb848da3fa025"><gtr:id>6542cfc5594084c9f07eb848da3fa025</gtr:id><gtr:otherNames>Prak K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>56e13dbfcb4175.02208634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D40BA99D-D889-4411-A48F-FE17EFC4AF3D</gtr:id><gtr:title>Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ad80b0f6f78f1f483527d5a3124bb1"><gtr:id>53ad80b0f6f78f1f483527d5a3124bb1</gtr:id><gtr:otherNames>Nunes JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56e0625b90be73.74950707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7215DA24-8F59-4BAF-B751-AA605C44B9D3</gtr:id><gtr:title>A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fa01e6c47c2d7880aef1437711c3be5"><gtr:id>1fa01e6c47c2d7880aef1437711c3be5</gtr:id><gtr:otherNames>Ohnmacht SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56e05eb9e3cec5.66898671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>785A872C-482C-458B-AF99-C1C464EC95D0</gtr:id><gtr:title>Bromomaleimide-linked bioconjugates are cleavable in mammalian cells.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f65be00d6b1ceda2023c6297ec494126"><gtr:id>f65be00d6b1ceda2023c6297ec494126</gtr:id><gtr:otherNames>Moody P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>5463280f7b2b91.09896690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E8136C5-F46A-4636-B973-0CC7DD0F56A6</gtr:id><gtr:title>Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d5f6c35cd5992f904f05a8c4de4dd6"><gtr:id>88d5f6c35cd5992f904f05a8c4de4dd6</gtr:id><gtr:otherNames>Lansdell SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>5463603121e869.07452597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C6E10CC-46CD-434E-86DC-ECE60CD977A5</gtr:id><gtr:title>Bromo- and thiomaleimides as a new class of thiol-mediated fluorescence 'turn-on' reagents.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c80e34933f96f637c06275c00a39371"><gtr:id>7c80e34933f96f637c06275c00a39371</gtr:id><gtr:otherNames>Youziel J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56e13c62bfd564.28566498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>157511E7-2AA2-49B3-8EB4-F2FF28A1B5EC</gtr:id><gtr:title>Next-generation disulfide stapling: reduction and functional re-bridging all in one.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/313cab65ad41f0990bbf3b8e221af774"><gtr:id>313cab65ad41f0990bbf3b8e221af774</gtr:id><gtr:otherNames>Lee MTW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>56e0625b41cb00.48279449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30496CAC-41AC-4D75-A420-9EE12F96297B</gtr:id><gtr:title>Fluorescence-guided development of a tricistronic vector encoding bimodal optical and nuclear genetic reporters for in vivo cellular imaging.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e46450847bc63d817ad16c0a2311cb"><gtr:id>a9e46450847bc63d817ad16c0a2311cb</gtr:id><gtr:otherNames>Badar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56e13e9eed28e5.03816234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48521F21-A760-4C0B-BCF2-A68579B16DF4</gtr:id><gtr:title>A novel synthetic chemistry approach to linkage-specific ubiquitin conjugation.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf44462bece01a3aadb645e6b94a7383"><gtr:id>bf44462bece01a3aadb645e6b94a7383</gtr:id><gtr:otherNames>Morgan RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56e0625bb26723.73986936</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12024</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>